Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Livzon Pharmaceutical Group ( (HK:1513) ) has shared an update.
Livzon Pharmaceutical Group Inc. announced the cancellation of 7,245,300 repurchased H Shares, which accounted for 0.80% of its total issued share capital. This move, compliant with the H Share Repurchase Mandate, will reduce the company’s registered capital by RMB7,245,300, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$24.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, production, and sale of pharmaceutical products. The company is known for its wide range of medical products and services, catering to various healthcare needs.
Average Trading Volume: 999,074
Technical Sentiment Signal: Buy
Current Market Cap: HK$30.95B
Learn more about 1513 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue